Morgan Stanley lists biotechs with negative enterprise value, 2022 catalysts (NASDAQ:GLPG)
seekingalpha.com
business
2022-05-31 01:06:50

ipopba/iStock via Getty Images Reviewing its coverage on biotechs with negative enterprise values, Morgan Stanley says that the number of companies on the list with potential catalysts in 2022 has increased to 27 in May from 20 previously. Adding market capitalization to total debt and deducting cash and cash equivalents, the enterprise value indicates the actual value of the company's business operations. Belgian biotech Galapagos NV (NASDAQ:GLPG) (OTC:GLPGF) tops the list with the largest negative enterprise value, followed by its U.
